FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Michael Scholz et al.|The Lancet Oncology|2014Cited by 1.7k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Volker Heinemann, Dominik Paul Modest et al.|The Lancet Oncology|2016Cited by 417
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialSebastian Stintzing, Volker Heinemann, Pratyaksha Wirapati et al.|Annals of Oncology|2019Cited by 194
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialVolker Heinemann, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al.|British Journal of Cancer|2020Cited by 187
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Volker Heinemann, Lisa Miller‐Phillips et al.|European Journal of Cancer|2017Cited by 139